Safety of biologic therapy in rheumatoid arthritis (Q37944433)

25 August 2017

Safety of biologic therapy in rheumatoid arthritis (English)

1 reference

25 August 2017

1 reference

Eric M Ruderman

2

0 references

author name string

Robert S Woodrick

series ordinal

1

1 reference

PubMed ID

21989284

25 August 2017

language of work or name

English

0 references

publication date

11 October 2011

1 reference

Nature Reviews Rheumatology

25 August 2017

1 reference

25 August 2017

7

1 reference

25 August 2017

11

1 reference

25 August 2017

639-652

1 reference

https://scigraph.springernature.com/pub.10.1038/nrrheum.2011.145

25 August 2017

0 references

cites work

Signalling pathways of the TNF superfamily: a double-edged sword

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with specia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Addressing the safety of anakinra in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Anakinra for rheumatoid arthritis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

B cell non-Hodgkin's lymphoma: rituximab safety experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Granulomatous infectious diseases associated with tumor necrosis factor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Effects of tumor necrosis factor alpha on dendritic cell accumulation in lymph nodes draining the immunization site and the impact on the anticryptococcal cell-mediated immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Pneumocystis carinii pneumonia in a rheumatoid arthritis patient treated with adalimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Rituximab-associated infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Prevalence of Antibodies in Human Sera against JC Virus, an Isolate from a Case of Progressive Multifocal Leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Autoimmune Diseases Induced by TNF-Targeted Therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Dermatological complications and safety of anti-TNF treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Clinical safety of tocilizumab in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Safety profile of abatacept in rheumatoid arthritis: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Immediate type I hypersensitivity response implicated in worsening injection site reactions to adalimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Adverse cutaneous reactions induced by TNF-alpha antagonist therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

The mortality of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Inflammatory demyelinating events following treatment with anti-tumor necrosis factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Optic neuritis associated with adalimumab in the treatment of uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Can tumor necrosis factor inhibitors be safely used in pregnancy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

A safety assessment of tumor necrosis factor antagonists during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Pregnancy outcomes after maternal exposure to rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Infections in patients with rheumatoid arthritis treated with biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Infection in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Adverse effects of biologics: a network meta-analysis and Cochrane overview

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-b

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group st

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Pneumocystis carinii pneumonia in a patient on etanercept for psoriatic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Asymptomatic carriage of Pneumocystis jiroveci in elderly patients with rheumatoid arthritis in Japan: a possible association between colonization and development of Pneumocystis jiroveci pneumonia during low-dose MTX therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Vaccines for prophylaxis of viral infections in patients with hematological malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Cutaneous events during treatment of chronic inflammatory joint disorders with anti-tumour necrosis factor alpha: a cross-sectional study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

The appearance of pustular psoriasis during antitumor necrosis factor therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Development of psoriasis after B cell depletion with rituximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Skin manifestations induced by TNF-alpha inhibitors in juvenile idiopathic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Elevated circulating levels of tumor necrosis factor in severe chronic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2011.145

Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors.

31 March 2020

1 reference

12 December 2020

Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response.

1 reference

12 December 2020

Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship

1 reference

12 December 2020

Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab.

1 reference

12 December 2020

Increased risk of malignancy in patients with systemic lupus erythematosus.

1 reference

12 December 2020

Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis.

1 reference

12 December 2020

Production of tumor necrosis factor alpha, interleukin-1 alpha, and interleukin-6 during murine coccidioidomycosis.

1 reference

12 December 2020

Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2011.145

1 reference

release_bktfgjhlqfeavjwmulu5f4wkiu

25 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bktfgjhlqfeavjwmulu5f4wkiu

24 November 2022

mapped directly with Wikidata item

PubMed ID

21989284

1 reference

PubMed ID

21989284